(4S)-3-(benzyloxycarbonyl)-2,2-dimethyl-4-(3-oxo-propyl)oxazolidine | 222027-19-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4S)-3-(benzyloxycarbonyl)-2,2-dimethyl-4-(3-oxo-propyl)oxazolidine
• 英文别名: (S)-2,2-dimethyl-4-(3-oxo-propyl)-oxazolidine-3-carboxylic acid benzyl ester；(S)-2,2-dimethyl-4-(3-oxo-propyl)oxazolidine-3-carboxylic acid benzyl ester；benzyl (4S)-2,2-dimethyl-4-(3-oxopropyl)-1,3-oxazolidine-3-carboxylate
• CAS: 222027-19-2
• 化学式: C₁₆H₂₁NO₄
• 分子量: 291.347
• InChiKey: ICMYCTQKZAAVAB-AWEZNQCLSA-N

物化性质

• 沸点：
  420.7±40.0 °C(Predicted)
• 密度：
  1.125±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  55.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (4S)-3-(benzyloxycarbonyl)-2,2-dimethyl-4-(3-oxo-propyl)oxazolidine 在 palladium on activated charcoal 四氢吡咯 、 锂硼氢 、 四(三苯基膦)钯 、 四丁基氟化铵 、 氢气 作用下， 生成 ((S)-6-{[(S)-1-((R)-2-tert-Butoxycarbonylamino-3-phenyl-propionyl)-pyrrolidine-2-carbonyl]-amino}-7-oxo-7-thiazol-2-yl-heptyl)-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Peptidyl α-keto thiazole as potent thrombin inhibitors

  摘要：

  We report the synthesis and evaluation of alpha-keto thiazole derivatives such as D-Phe-Pro-Arg-thiazole 9 as a novel type of thrombin inhibitor. Tripeptidyl alpha-keto thiazole 9 exhibited the inhibitory activity of thrombin at nanomolar levels and showed a more potent prolongation effect on clotting time than argatroban at a dose of 3 mg/kg intravenously. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)00057-7
• 作为产物：
  描述：

  (S)-2-Benzyloxycarbonylamino-pentanedioic acid 5-methyl ester 在 sodium tetrahydroborate 、 二异丁基氢化铝 、 对甲苯磺酸 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 甲醇 、 乙酸乙酯 、 甲苯 、 苯 为溶剂， 反应 1.0h， 生成 (4S)-3-(benzyloxycarbonyl)-2,2-dimethyl-4-(3-oxo-propyl)oxazolidine
  参考文献：
  名称：

  A synthetic approach to diaryl ethers using the Robinson annulation

  摘要：

  An alternative synthetic approach to diaryl ethers has been developed. In the key transformation, Robinson annulation of nonracemic aldehydes 16a,b, derived from L-glutamic acid 5-methyl ester and phenoxymethylvinyl ketone, provided alpha-phenoxyenones 17a,b. The Cbz-protected oxazolidine 17b was further converted into the diaryl ether 18b utilizing an oxidative selenation protocol. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0957-4166(98)00466-2

文献信息

• NOVEL HETEROCYCLYL COMPOUNDS
  申请人：Aebi Johannes

  公开号：US20100016282A1

  公开（公告）日：2010-01-21

  The invention is concerned with novel heterocyclyl compounds of formula (I) wherein A, X, Y 1 , Y 2 , Y 3 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , m, n and p are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.

  该发明涉及式(I)的新异环丙基化合物，其中A、X、Y1、Y2、Y3、R3、R4、R5、R6、R7、R8、R9、R10、m、n和p的定义如描述和索赔中所述，并且其生理上可接受的盐。这些化合物是CCR2受体、CCR5受体和/或CCR3受体的拮抗剂，可以用作药物。
• [EN] BICYCLIC HETEROCYCLES AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS<br/>[FR] HÉTÉROCYCLES BICYCLIQUES ET LEUR UTILISATION EN TANT QU'ANTAGONISTES DU RÉCEPTEUR CCR2
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011042399A1

  公开（公告）日：2011-04-14

  The invention is concerned with novel bicyclic compounds of formula (I), wherein A, L, E, F, G, R1, R2, R3, R4, R5, R6, R7, V, W and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.

  这项发明涉及具有以下结构式（I）的新颖双环化合物，其中A、L、E、F、G、R1、R2、R3、R4、R5、R6、R7、V、W和n如描述和权利要求中所定义，并且其生理上可接受的盐。这些化合物是CCR2受体、CCR5受体和/或CCR3受体的拮抗剂，可用作药物。
• NOVEL BICYCLIC COMPOUNDS
  申请人：Aebi Johannes

  公开号：US20110082294A1

  公开（公告）日：2011-04-07

  The invention is concerned with novel bicyclic compounds of formula (I), wherein A, L, E, F, G, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , V, W and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.

  该发明涉及具有以下结构的新型双环化合物（I），其中A、L、E、F、G、R1、R2、R3、R4、R5、R6、R7、V、W和n的定义如描述和索赔中所定义，并且其生理上可接受的盐。这些化合物是CCR2受体、CCR5受体和/或CCR3受体的拮抗剂，可用作药物。
• NOVEL HETEROCYCLYL COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISEASE
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2307387A1

  公开（公告）日：2011-04-13
• BICYCLIC HETEROCYCLES AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS
  申请人：F.Hoffmann-La Roche AG

  公开号：EP2486042A1

  公开（公告）日：2012-08-15